Teprotumumab

Drug Profile

Teprotumumab

Alternative Names: Insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human) - River Vision Development; R 1507; RG 1507; RV 001

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genmab; Roche
  • Developer River Vision Development Corp; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graves ophthalmopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graves ophthalmopathy
  • Phase I Diabetic macular oedema
  • Discontinued Advanced breast cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 01 Aug 2016 River Vision Development completes a phase I trial for Diabetic macular oedema in USA (NCT02103283)
  • 01 Oct 2014 Phase-I clinical trials in Diabetic macular oedema in USA (IV) (NCT02103283)
  • 27 Mar 2014 River Vision Development plans a phase I trial for Diabetic macular oedema in USA (NCT02103283)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top